Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors

• Cure rates are high for choriocarcinoma, however chemoresistant disease often leads to death. • High expression of PD-L1 suggests a role for checkpoint inhibitors in choriocarcinoma. • Pembrolizumab should be considered for salvage therapy for chemoresistant choriocarcinoma.

Detalles Bibliográficos
Autores principales: Clair, Kiran H., Gallegos, Nicolas, Bristow, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490982/
https://www.ncbi.nlm.nih.gov/pubmed/32964090
http://dx.doi.org/10.1016/j.gore.2020.100625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490982/
https://www.ncbi.nlm.nih.gov/pubmed/32964090
http://dx.doi.org/10.1016/j.gore.2020.100625

Ejemplares similares